Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11597794 | 0.85 | LMNA (0.47) | HDAC4HDAC7HDAC5L3MBTL1SMN1; SMN2 | |
| SCHEMBL1041533 | 0.85 | MMP8 (0.51) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL3541681 | 0.84 | MEN1 (0.49) | L3MBTL1SMN1; SMN2CYP1A2CYP3A4TSHR | |
| SCHEMBL2798571 | 0.83 | CA12 (0.48) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL7796149 | 0.83 | PSEN1 (0.50) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL27537598 | 0.83 | CA12 (0.48) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL1395571 | 0.82 | CA12 (0.55) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL11597064 | 0.82 | SMN1; SMN2 (0.50) | HDAC4HDAC7HDAC5L3MBTL1SMN1; SMN2 | |
| SCHEMBL4517176 | 0.81 | L3MBTL1 (0.49) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL5321055 | 0.81 | CA12 (0.47) | CA12CA1CA2CA9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117604047-A | Preparation method of high-purity DHA ethyl ester | 华南理工大学 | 2024-02-27 | — | — | CN | claimed |
| US-4080207-A | Radiation-sensitive compositions and photographic elements containing N-(acylhydrazinophenyl) thioamide nucleating agents | EASTMAN KODAK COMPANY (US) | 1978-03-21 | — | — | US | claimed |
| CN-115896191-B | Preparation method of phospholipid DHA and microcapsule embedding method | 润科生物工程（福建）有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| EP-3763364-B1 | SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACID | MOCHIDA PHARM CO LTD (JP) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025090465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025090480-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-119867010-A | Egg rich in DHA nutrients and production method thereof | 青岛藻源海洋生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119837197-A | DHA nutrient for poultry, production method and application thereof | 青岛藻源海洋生物科技有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-115478084-B | Preparation method of polyunsaturated fatty acid ester | 嘉必优生物技术（武汉）股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-4468884-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-12-04 | — | — | EP | disclosed |
| WO-2011115813-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | WO | disclosed |
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7635715-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2111399-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008076427-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-5210160-A | PREPARATION OF HOMOPOLYMERS OF ETHENE AND COPOLYMERS OF ETHENE WITH HIGHER A-MONOOLEFINS USING A ZIEGLER CATALYST SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 1993-05-11 | — | — | US | disclosed |
| US-4066785-A | Esters of α-hydroperoxy-bis-p-halo-phenylacetic acids | YEDA RESEARCH & DEVELOPMENT CO., LTD. (IL) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | EGLN2, EGLN3, HIF1AN | CA12 2760/4885CA1 2235/4885CA2 1160/4885 |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | EGLN2, EGLN3, HIF1AN | CA12 2760/4885CA1 2235/4885CA2 1160/4885 |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | CNR1, SCN1B, OPRL1 | CA12 1327/4885CA1 781/4885CA2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.